NewslettersHuman Immunology NewsUncategorizedPD-1 Blockade with Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma: A Multicentre, Single-Arm, Phase II StudyBy Justin.choi - March 15, 2022050Investigators evaluated the activity of pembrolizumab in classic and endemic Kaposi sarcoma with cutaneous extension requiring systemic treatment.[Lancet Oncology] 6445212 AAAAAAAA items 1 apa 0 default asc 1 172904 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Abstract